scPharmaceuticals Past Earnings Performance

Past criteria checks 0/6

scPharmaceuticals's earnings have been declining at an average annual rate of -17.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 91.4% per year.

Key information

-17.9%

Earnings growth rate

-0.3%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate91.4%
Return on equity-260.9%
Net Margin-264.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How scPharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2SX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2430-807312
30 Jun 2424-616512
31 Mar 2418-586012
31 Dec 2314-555312
30 Sep 237-504411
30 Jun 234-453611
31 Mar 232-402913
31 Dec 220-372116
30 Sep 220-351618
30 Jun 220-311218
31 Mar 220-291016
31 Dec 210-281016
30 Sep 210-281115
30 Jun 210-311217
31 Mar 210-321218
31 Dec 200-321218
30 Sep 200-351125
30 Jun 200-321025
31 Mar 200-31925
31 Dec 190-33825
30 Sep 190-27817
30 Jun 190-27816
31 Mar 190-291116
31 Dec 180-291416
30 Sep 180-311517
30 Jun 180-311416
31 Mar 180-281215
31 Dec 170-24914
30 Sep 170-22714
30 Jun 170-26814
31 Mar 170-24712
31 Dec 160-24612

Quality Earnings: 2SX is currently unprofitable.

Growing Profit Margin: 2SX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2SX is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.

Accelerating Growth: Unable to compare 2SX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2SX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: 2SX has a negative Return on Equity (-260.88%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:10
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

scPharmaceuticals Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
null nullBMO Capital Markets Equity Research
Chase KnickerbockerCraig-Hallum Capital Group LLC